|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2001-5-29
|
|
pubmed:abstractText |
A series of 1,3,4-trisubstituted pyrrolidines was discovered to have the ability to displace [(125)I]-MIP-1alpha from the CCR5 receptor expressed on Chinese hamster ovary (CHO) cell membranes. CCR5 activity was found to be dependent on the regiochemistry and the absolute stereochemistry of the pyrrolidine.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
4
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1437-40
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11378372-Animals,
pubmed-meshheading:11378372-Binding, Competitive,
pubmed-meshheading:11378372-CHO Cells,
pubmed-meshheading:11378372-Chemokine CCL4,
pubmed-meshheading:11378372-Cricetinae,
pubmed-meshheading:11378372-Iodine Radioisotopes,
pubmed-meshheading:11378372-Macrophage Inflammatory Proteins,
pubmed-meshheading:11378372-Molecular Conformation,
pubmed-meshheading:11378372-Pyrrolidines,
pubmed-meshheading:11378372-Receptors, CCR5,
pubmed-meshheading:11378372-Transfection
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements.
|
|
pubmed:affiliation |
Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA. jeffrey_hale@merck.com
|
|
pubmed:publicationType |
Journal Article
|
